|
Last Updated: Nov 18, 2006 - 12:32:53 PM |
Latest Research
:
Musculoskeletal
:
Pagets Disease
Single Infusion of Zoledronic Acid More Effective in Paget�s Disease
A head-to-head study published in The New England Journal of Medicine reports that a single infusion of the investigational bisphosphonate, zoledronic acid 5 mg solution, offers superior efficacy, longer period of remission, and faster onset of action compared to the oral bisphosphonate risedronate (Actonel�) in patients with Paget�s disease.
Sep 8, 2005 - 1:08:00 AM
Latest Research
:
Musculoskeletal
:
Pagets Disease
Studies confirm new treatments for Paget's disease
Two studies led by researchers at The University of Auckland's Faculty of Medical and Health Sciences have pioneered new, more effective treatment for two forms of Paget's disease - a chronic and often painful bone disease.
Sep 5, 2005 - 11:56:00 PM
Latest Research
:
Musculoskeletal
:
Pagets Disease
European Commission Approves Zoledronic acid for the Treatment of Paget's Disease of Bone
Novartis Pharma AG announced today that Aclasta� (zoledronic acid 5mg solution for infusion) has been granted Marketing Authorization by the European Commission for the treatment of Paget's disease of the bone in all 25 European member states, as well as Norway and Iceland. This represents the first approval for Aclasta.
Apr 24, 2005 - 8:13:00 AM
<< prev
next >>
|
